We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Emtricitabine and Tenofovir Disoproxil Fumarate 200mg/300mg Tablets (Laurus Labs, USA)
Section 19A approved medicine
Emtricitabine and Tenofovir Disoproxil Fumarate 200mg/300mg Tablets (Laurus Labs, USA)
Section 19A approval holder
Phero Pharma Pty Ltd ABN 96 673 730 231
Phone
1800 720 020
Approved until
Status
Current
Medicines in short supply/unavailable
CIPLA TENOFOVIR + EMTRICITABINE 300/200 Tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg tablet bottle pack - ARTG 327898
Tenofovir/Emtricitabine 300/200 ARX tenofovir disoproxil fumarate 300 mg emtricitabine 200 mg tablet blister pack - ARTG 275070
TENOFOVIR DISOPROXIL EMTRICITABINE VIATRIS 300/200 tenofovir disoproxil maleate 300 mg and emtricitabine 200 mg film coated tablet bottle - ARTG 265834
TENOFOVIR / EMTRICITABINE SANDOZ 301/200 tenofovir disoproxil succinate / emtricitabine 301 mg/200 mg film-coated tablet bottle - ARTG 326237
Tenofovir/Emtricitabine 300/200 ARX tenofovir disoproxil fumarate 300 mg emtricitabine 200 mg tablet blister pack - ARTG 275070
TENOFOVIR DISOPROXIL EMTRICITABINE VIATRIS 300/200 tenofovir disoproxil maleate 300 mg and emtricitabine 200 mg film coated tablet bottle - ARTG 265834
TENOFOVIR / EMTRICITABINE SANDOZ 301/200 tenofovir disoproxil succinate / emtricitabine 301 mg/200 mg film-coated tablet bottle - ARTG 326237
Indication(s)
Indicated for the treatment of HIV infected adults over the age of 18 years, in combination with other antiretroviral agents.
Indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and in heterosexual serodiscordant couples.
Images
